International Journal of Hematology

, Volume 77, Issue 5, pp 503–511 | Cite as

Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma

  • Michinori Ogura
  • Yoshitoyo Kagami
  • Hirofumi Taji
  • Ritsuro Suzuki
  • Kazuhisa Miura
  • Takahiro Takeuchi
  • Yasuo Morishima


A pilot phase I/II study was conducted as a single-institute trial for evaluation of the feasibility and efficacy of a new salvage chemotherapy, CHASE, for patients with refractory or relapsed lymphoma. The CHASE regimen, consisting of cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone, was administered every 3 weeks in a maximum of 5 courses. A total of 16 patients were eligible and registered for this study. Myelosuppression was the major toxicity. Although grade 4 leukopenia and grade 3 thrombocytopenia were identified in 15 and 16 patients, respectively, duration of the nadir was brief (median, 3 days). Nonhematological grade 4 toxicity was not observed, and transient elevations of bilirubin and grade 3 aspartate aminotransferase/alanine aminotransferase (AST/ALT) were observed in 2 and 3 courses, respectively, in a total of 57 courses. Complete and partial response rates were 71.4% (10/14) and 7.1% (1/14), respectively. The median percentage of maximal CD34+ cells was 6.1% on day 15, and a median number of 1.88 X 106 CD34+ cells/kg per apheresis were obtained. Thirteen patients received high-dose chemoradiotherapy followed by autologous peripheral blood stem cell transplantation. With a median follow-up time of 36 months from the start of CHASE, the overall survival rate for the 16 patients was 66.6%. These results indicated that CHASE is a safe and effective salvage regimen for malignant lymphoma, has sufficient mobilizing effect on peripheral blood stem cells, and warrants further phase II study.

Key words

CHASE therapy Relapsed lymphoma Salvage chemotherapy PBSC mobilization Auto-PBSCT 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Devita VT Jr, Serpick AA, Carbone PP. Combination chemo- therapy in the treatment of advanced Hodgkin’s disease.Ann Intern Med. 1970;73:881–895.CrossRefPubMedGoogle Scholar
  2. 2.
    Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease.J Clin Oncol. 1986;4:1295–1306.CrossRefPubMedGoogle Scholar
  3. 3.
    Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.Cancer. 1975;36:252–259.CrossRefPubMedGoogle Scholar
  4. 4.
    Bonadonna G, Valagussa P, Santoro A. Alternating non-cross- resistant combination chemotherapy or MOPP in stage IV Hodg- kin’s disease: a report of 8-year results.Ann Intern Med. 1986;104: 739–746.CrossRefPubMedGoogle Scholar
  5. 5.
    Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alter- nating with ABVD.N Engl J Med. 1992;327:1478–1484.CrossRefPubMedGoogle Scholar
  6. 6.
    Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.Ann Intern Med. 1985;102:596–602.CrossRefPubMedGoogle Scholar
  7. 7.
    Coiffier B, Bryon PA, Berger F, et al. Intensive and sequential com- bination chemotherapy for aggressive malignant lymphomas (pro- tocol LNH-80).J Clin Oncol. 1986;4:147–153.CrossRefPubMedGoogle Scholar
  8. 8.
    Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of Pro- MACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trialJ Clin Oncol. 1991;9:25–38.CrossRefPubMedGoogle Scholar
  9. 9.
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.N Engl J Med. 1993;328: 1002–1006.CrossRefPubMedGoogle Scholar
  10. 10.
    Velasquez W, Fuller LM, Oh KK et al. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas.Cancer. 1984;53:1478–1483.CrossRefPubMedGoogle Scholar
  11. 11.
    DeVita VT Jr. Hodgkin’s disease: conference summary and future directions.Cancer Treat Rep. 1982;66:1045–1055.Google Scholar
  12. 12.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475.CrossRefPubMedGoogle Scholar
  13. 13.
    Anderson T, Bender RA, Fisher RI et al. Combination chemo- therapy in non-Hodgkin’s lymphoma: results of long-term fol- lowup.Cancer Treat Rep. 1977;61:1057–1066.PubMedGoogle Scholar
  14. 14.
    Dana BW, Dahlberg S, Nathwani B, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.J Clin Oncol. 1993;11:644–651.CrossRefPubMedGoogle Scholar
  15. 15.
    Lister TA. The management of follicular lymphoma.Ann Oncol. 1991;2(suppl 2):131–135.CrossRefPubMedGoogle Scholar
  16. 16.
    Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma.J Clin Oncol. 1987;5:407–412.CrossRefPubMedGoogle Scholar
  17. 17.
    Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high- dose Ara-C and dexamethasone (DHAP).Blood. 1988;71:117–122.PubMedGoogle Scholar
  18. 18.
    Dana BW, Dahlberg S, Miller TP, et al. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.J Clin Oncol. 1990;8:1155–1162.CrossRefPubMedGoogle Scholar
  19. 19.
    Weick JK, Dahlberg S, Fisher RI et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin’s lymphoma with MACOP-B: a Southwest Oncology Group study.J Clin Oncol. 1991;9:748–753.CrossRefPubMedGoogle Scholar
  20. 20.
    Gams RA, Rainey M, Dandy M, Bartolucci AA., Silberman H, Omura G. Phase III study of BCOP v CHOP in unfavorable cate- gories of malignant lymphoma: a Southeastern Cancer Study Group trial.J Clin Oncol. 1985;3:1188–1195.CrossRefPubMedGoogle Scholar
  21. 21.
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone mar- row transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.N Engl J Med. 1995;333:1540–1545.CrossRefPubMedGoogle Scholar
  22. 22.
    Kasakura S. Recent developments in basic and clinical hemato- poietic stem cell transplantation [editorial].Int J Hematol. 2003; 77:1–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow trans- plantation for B-cell lymphomaN Engl J Med. 1991;25:1525–1533.CrossRefGoogle Scholar
  24. 24.
    Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999;94:3325–3333.PubMedGoogle Scholar
  25. 25.
    Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autol- ogous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial.Lancet. 2002;359:2065–2071.CrossRefPubMedGoogle Scholar
  26. 26.
    Kantarjian H, Barlogie B, Plunkett W, et al. High-dose cytosine ara- binoside in non-Hodgkin’s lymphoma.J Clin Oncol. 1983;1: 689–694.CrossRefPubMedGoogle Scholar
  27. 27.
    Velasquez WS, McLaughlin P,Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.J Clin Oncol. 1994;12:1169–1176.CrossRefPubMedGoogle Scholar
  28. 28.
    Ohkubo T, Hori H, Higashigawa M, et al. Synergistic interaction between etoposide and 1-beta-D-arabinofuranosylcytosine.Adv Exp Med Biol. 1989;253B:355–362.CrossRefPubMedGoogle Scholar
  29. 29.
    Chang TT, Gulati SC, Chou TC et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by com- puter analysis.Cancer Res. 1985;45:2434–2439.PubMedGoogle Scholar
  30. 30.
    Ogura M, Kagami Y, Suzuki R, et al. Phase I/II trial of cure- oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomag- netic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.Cancer Chemother Pharma- col. 1997;40(suppl):S51-S57.CrossRefGoogle Scholar
  31. 31.
    Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.Jpn J Clin Oncol. 1993;23:250–257.PubMedGoogle Scholar
  32. 32.
    Adelstein DJ, Lazarus HM, Hines JD, Herzig RH. High-dose cyto- sine arabinoside in previously treated patients with poor-prognosis non-Hodgkin’s lymphoma.Cancer. 1985;56:1493–1496.CrossRefPubMedGoogle Scholar
  33. 33.
    Freedman A, Gribben J, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.Blood. 1996;88:2780–2786.PubMedGoogle Scholar
  34. 34.
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemo- therapy.J Clin Oncol. 1999;17:268–276.CrossRefPubMedGoogle Scholar
  35. 35.
    Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxi- city and efficacy in relapsed and refractory non-Hodgkin’s lym- phoma.J Clin Oncol. 1993;11:1573–1582.CrossRefPubMedGoogle Scholar
  36. 36.
    Olivieri A, Offidani M, Ciniero L, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma.Bone Marrow Trans- plant. 1995;16:85–93.Google Scholar
  37. 37.
    Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.Blood. 1994;83: 636–640.PubMedGoogle Scholar
  38. 38.
    Freedman A, Neuberg D, Mauch P, et al. Cyclophosphamide, dox- orubicin, vincristine, prednisone dose intensification with granulo- cyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.Blood. 1997;90: 4996–5000.PubMedGoogle Scholar
  39. 39.
    Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lym- phoma.Br J Haematol. 2000;109:729–735.CrossRefPubMedGoogle Scholar
  40. 40.
    Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.Blood. 2000;96:864–869.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Michinori Ogura
    • 1
  • Yoshitoyo Kagami
    • 1
  • Hirofumi Taji
    • 1
  • Ritsuro Suzuki
    • 1
  • Kazuhisa Miura
    • 1
  • Takahiro Takeuchi
    • 1
  • Yasuo Morishima
    • 1
  1. 1.Department of Hematology and ChemotherapyAichi Cancer Center HospitalAichiJapan

Personalised recommendations